AzTrials
AzTrials

Acute DiarrheaNCT02896465

Human Milk Oligosaccharides and Childhood Diarrhoea

A study testing Oral rehydration solution, Zinc and Human milk oligosaccharides in people with Acute Diarrhea, run by Société des Produits Nestlé (SPN) at 1 site in Bangladesh.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Assessment of the impact of oral Human Milk Oligosaccharides (HMO) application on acute diarrhoea and the development of prolonged and persistent diarrhoea in paediatric patients hospitalized with acute diarrhoea. Read more about this study

Who is it for?
Ages 6 months to 2 years
Conditions the study is for
Acute Diarrhea
What is being tested?
Oral rehydration solution, Zinc and Human milk oligosaccharides
Type of treatment
Pill or oral medicine
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
435 participants
Where
1 siteBangladesh
Study dates
Jun 2016to Feb 2019
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 6 months to 2 years
  • All sexes
  • No healthy volunteers
  • Child

Inclusion Criteria: Non breast-fed children (group I and group II):

  1. Both male and female children between the ages of 6 months to 2 years.
  2. Acute diarrhoea (<48 hours) without interfering co-morbidities, e.g. acute respiratory tract infection, sepsis, gross electrolyte imbalances etc.
  3. Guardian is willing to have the child admitted to the hospital as an inpatient until resolution of diarrhea and to return to the clinic with the child on Day 14 after admission for a final evaluation.
  4. Written informed consent must be obtained prior to admission to this study.
  5. The subject has a physical examination that reveals no clinically significant abnormalities other than those expected for subjects with acute infectious diarrhea.

Exclusion Criteria: Non breast-fed children (group I and group II):

  1. Children of either sex who are fully or partially breast-fed until one week before enrolment (since breastfed children receive naturally HMO, their inclusion into the ORS/zinc or HMO/ORS/zinc arms would critically interfere with the study question; depending on children's age 30 to 50 % of mothers would do so at icddr,b). However, an unblinded reference group will be constituted by age-matched children who are breastfed at the moment of hospitalization for acute diarrhea and where the mothers want to continue breastfeeding on the study ward (so breastfeeding is only an exclusion for the randomized groups).
  2. Suspected or confirmed cholera as detected by a positive DF examination in stool collected on admission. (The large volume and quick evacuation of stool could interfere with product presence in the gut)
  3. Symptom duration > 48 hours at screening.
  4. Vomiting severity that is likely to make administration and retention of test product impossible.
  5. Severe malnutrition defined (using z-scores) as: severe stunting (SS; height-for-age z-score < -3.00); severe underweight (SU; weight-for-age z-score < -3.00), and severe wasting (SW; weight-for-height z-score < -3.00), using the World Health Organization reference value. Moderate malnutrition was defined as follows: moderate stunting (height-for-age z-score -3.00 to < -2.00); moderate underweight (weight-for-age z-score -3.00 to < -2.00); and moderate wasting (weight-for-height z-score -3.00 to < -2.00). We considered children as well-nourished if their z-scores for weight-for-age, height-for-age and weight-for-height z-score were form -2.00 to +1.00. Children with moderate malnutrition will be enrolled since they develop with higher frequency PD).
  6. Child already receiving antibiotics or anti-motility drugs for this diarrhea episode prior to screening.
  7. Children with any food allergy.

Breast-fed children, (Group III - Reference group)

  1. Exclusive Breastfed children Either sex: Male and female
  2. Age 6-12 month
  3. Acute diarrhoea (<48 hours) without interfering co-morbidities, e.g. acute respiratory tract infection, sepsis, gross electrolyte imbalances etc.
  4. Written informed consent must be obtained prior to admission to this study.
  5. The subject has a physical examination that reveals no clinically significant abnormalities other than those expected for subjects with acute infectious diarrhea.

Trial locations and contacts

1 site in 1 country.

Bangladesh1 site
  • International Center for Diarrheal Disease Research

    Dhaka

Other trials in Bangladesh

About this study

Official title: Treatment of Acute Childhood Diarrhoea With Human Milk Oligosaccharides and Impact on Gut Micro Biota Dysbiosis and Nutritional Status

Assessment of the impact of oral Human Milk Oligosaccharides (HMO) application on acute diarrhoea and the development of prolonged and persistent diarrhoea in paediatric patients hospitalized with acute diarrhoea.

Read the detailed description

The trial is single site, double blind, randomized of HMO addition (1.5 g /day) to standard of care in paediatric diarrhoea patients. HMO application and follow-up of the children at home will be done for 2 weeks. Control patients receive only the standard of care (ORS plus zinc). A breastfed group of diarrhoea patients will serve as reference group.

The total sample size is 495 patients. Patients will be females and males aged 6 months to 2 years old with acute diarrhoea.

Conditions
Acute Diarrhea
Being tested
Oral rehydration solution, Zinc, Human milk oligosaccharides, Breastfeeding
Keywords
Children, Diarrhea, Human milk oligosaccharides
Medical subject headings
Diarrhea

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Oral rehydration solutionOther

    Also called ORS

  • ZincOther

  • Human milk oligosaccharidesOther

    Also called HMO

  • BreastfeedingOther

Study groups in NCT02896465
Study groupRoleWhat they receive
ORS+ZINCActive comparatorOral rehydration solution + Zinc
Receives: Other: Oral rehydration solution; Other: Zinc
ORS+ZINC+HMOExperimentalOral rehydration solution + Zinc + Human milk oligosaccharides
Receives: Other: Oral rehydration solution; Other: Zinc; Other: Human milk oligosaccharides
ORS+ZINC+BreastfeedingPlacebo comparatorOral rehydration solution + Zinc + Breastfeeding
Receives: Other: Oral rehydration solution; Other: Zinc; Other: Breastfeeding

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Improvement (change) of clinical symptoms of diarrhea

    Passage of the last abnormal stool prior to formed/ soft stools during two consecutive 8-hour periods.

    Measured: Day1, Day2, Day3, Day4, Day5, Day6, Day7

Secondary outcomes (8)
  1. Stools output

    Stools output, expressed as g/kg of body weight (cumulative output)

    Measured: Day1, Day2, Day3, Day4, Day5, Day6, Day7

  2. Weight gain

    Measured: Day1, Day2, Day3, Day4, Day5, Day6, Day7, Day14

  3. Adverse events

    Measured: Day1, Day2, Day3, Day4, Day5, Day6, Day7, Day14

  4. Daily stool frequency

    Measured: Day1, Day2, Day3, Day4, Day5, Day6, Day7

  5. The number of vomiting

    Measured: Day1, Day2, Day3, Day4, Day5, Day6, Day7

  6. The duration of vomiting

    Measured: Day1, Day2, Day3, Day4, Day5, Day6, Day7

  7. Change in Z-score

    Measured: Day1, Day14

  8. The amount of ORS to correct dehydration expressed as ml ORS /kg body weight, daily and cumulative input

    Measured: Day1, Day2, Day3, Day4, Day5, Day6, Day7

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted12 Sep 2016 (estimated)
  2. Study startJun 2016
  3. Primary completionOct 2018
  4. Study completionFeb 2019

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Other
Allocation
Randomised
Intervention model
Parallel groups
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
435 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02896465
Sponsor's protocol ID
13.26.INF
Status last verified
Jul 2019
First submitted
10 Aug 2016
Last updated
23 Jul 2019
Results posted
No
Data monitoring committee
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing Oral rehydration solution, Zinc and Human milk oligosaccharides in people with Acute Diarrhea, run by Société des Produits Nestlé (SPN) at 1 site in Bangladesh.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 23 Jul 2019. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Bangladesh. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Improvement (change) of clinical symptoms of diarrhea (time frame: Day1, Day2, Day3, Day4, Day5, Day6, Day7). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Jul 2019.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in